Literature DB >> 455239

Bladder carcinoma as a systemic disease.

G R Prout, P P Griffin, W U Shipley.   

Abstract

Pne hundred and fifty-one patients with transitional cell carcinoma of the bladder who were evaluated by conventional means preoperatively underwent a radical cystectomy. They were then classified according to the highest known pathological stage, first site of postoperative metastasis and the temporal relationship of the cystectomy to the appearance of the metastasis. Fifty patients developed metastases, 80% of which were proven histologically. Thirty-nine of fifty patients (78%) who developed metastases did so within a year of cystectomy. Extent of local tumor was directly related to the incidence of positive pelvic nodes. Metastases occurred most commonly in lung and bone. Soft tissues of the pelvis were involved in thirteen (16%) of the patients who developed metastatic carcinoma and those patients with positive pelvic nodes were more likely to have these kinds of recurrent disease. These evaluations suggest that the metastases must be present at cystectomy or as a result of it. The data imply the existence of appreciable heterogeneity among patients and/or their invasive bladder carcinoma. Disseminated but silent metastases suggest that a relationship between the primary tumor and the occurrence of metastatic disease may exist. Knowledge of this relationship is very important in planning subsequent therapeutic strategies.

Entities:  

Mesh:

Year:  1979        PMID: 455239     DOI: 10.1002/1097-0142(197906)43:6<2532::aid-cncr2820430654>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Neoadjuvant chemotherapy for bladder cancer.

Authors:  Peter C Black; Gordon A Brown; H Barton Grossman; Colin P Dinney
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  [Oncological diseases and postoperative alterations of the bladder and urinary tract].

Authors:  M M Ong; P Riffel; J Budjan; C Bolenz; S O Schönberg; S Haneder
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

3.  In vitro culturing of viable circulating tumor cells of urinary bladder cancer.

Authors:  Martin Cegan; Katarina Kolostova; Rafal Matkowski; Marek Broul; Jan Schraml; Marek Fiutowski; Vladimir Bobek
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).

Authors:  P H Smith; J A Child; J H Mulder; A T Van Oosterom; J A Martinez-Pineiro; B Richards; G Stoter; O Dalesio; M De Pauw; R Sylvester
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Clinical prognostic factors for radical cystectomy in bladder cancer.

Authors:  Seung Hyun Jeon; Sung-Hyun Jeon; Sung-Goo Chang
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

6.  Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.

Authors:  A Karl; S Tritschler; S Hofmann; C G Stief; C Schindlbeck
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

7.  Radical cystectomy versus alternative treatments for muscle-confined bladder cancer.

Authors:  A Tekin; F T Aki; H Ozen
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

8.  The chemotherapy of advanced bladder cancer.

Authors:  D W Newling; G Stoter; R Sylvester; M de Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy.

Authors:  Soichiro Yoshida; Fumitaka Koga; Shuichiro Kobayashi; Hiroshi Tanaka; Shiro Satoh; Yasuhisa Fujii; Kazunori Kihara
Journal:  World J Radiol       Date:  2014-06-28

10.  Adjuvant chemotherapy for non-organ confined disease after radical cystectomy.

Authors:  A Tekin; H Ozen
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.